Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting
Cost reduction associated with the use of rivaroxaban compared with the enoxaparin + warfarin combination for for deep vein thrombosis and pulmonary thromboembolism when treated in the inpatient setting. The choice of the cost reduction method is conditioned by the evidence from the randomized contr...
Main Authors: | , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Remedium Group LLC
2014-12-01
|
Series: | Медицинский совет |
Subjects: | |
Online Access: | https://www.med-sovet.pro/jour/article/view/610 |
id |
doaj-a7cf9369d2a1498985e9a4ea259d4225 |
---|---|
record_format |
Article |
spelling |
doaj-a7cf9369d2a1498985e9a4ea259d42252021-07-28T13:29:16ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902014-12-0108182310.21518/2079-701X-2014-8-18-23610Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient settingMV Avksentyeva0OV Shatalova1Center for Technology Assessment in Healthcare, Institute of Applied Economic Research of the RANEPA, Department of Public Health and Preventive Medicine, First Moscow State Medical University named after I.M. Sechenov, MoscowDepartment of Clinical Pharmacology and Intensive Therapy with Clinical Pharmacology Courses, school of postgraduate medical education, Department of Clinical Allergology, school of postgraduate medical education, Volgograd State Medical University, Russian Ministry of HealthCost reduction associated with the use of rivaroxaban compared with the enoxaparin + warfarin combination for for deep vein thrombosis and pulmonary thromboembolism when treated in the inpatient setting. The choice of the cost reduction method is conditioned by the evidence from the randomized controlled studies EINSTEIN DVT and EINSTEIN PE, stating that rivaroxaban is no less effective compared with enoxaparin in combination with warfarin. The difference in the cost of the drugs is calculated from the healthcare perspective taking into account the risk of major bleeding. The price values were sourced from public procurement tenders (zakupki.gov.ru) in quarters I-IV 2013 and quarter I 2014. Costs associated with the treatment of major bleeding were defined on the basis of the obligatory medical insurance rates for Moscow in 2013. The authors demonstrated that use of rivaroxaban compared with enoxaparin and warfarin results in cost savings for the medicinal treatment of DVT and PTE in the amount of 2,020.71 and 3,353.35 rubles per patient, respectively. The revealed pattern is resistant to real-life fluctuations in prices for medicines.https://www.med-sovet.pro/jour/article/view/610анализ минимизации затраттромбоз глубоких вен (тгв)тромбоэмболия легочных артерий (тэла)ривароксабанэноксапаринварфаринcost reduction evaluationdeep vein thrombosis (dvt)pulmonary thromboembolism (pte)rivaroxabanenoxaparinwarfarin |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
MV Avksentyeva OV Shatalova |
spellingShingle |
MV Avksentyeva OV Shatalova Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting Медицинский совет анализ минимизации затрат тромбоз глубоких вен (тгв) тромбоэмболия легочных артерий (тэла) ривароксабан эноксапарин варфарин cost reduction evaluation deep vein thrombosis (dvt) pulmonary thromboembolism (pte) rivaroxaban enoxaparin warfarin |
author_facet |
MV Avksentyeva OV Shatalova |
author_sort |
MV Avksentyeva |
title |
Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting |
title_short |
Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting |
title_full |
Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting |
title_fullStr |
Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting |
title_full_unstemmed |
Pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting |
title_sort |
pharmacoeconomic evaluation of treating acute venous thromboembolism with rivaroxaban in the inpatient setting |
publisher |
Remedium Group LLC |
series |
Медицинский совет |
issn |
2079-701X 2658-5790 |
publishDate |
2014-12-01 |
description |
Cost reduction associated with the use of rivaroxaban compared with the enoxaparin + warfarin combination for for deep vein thrombosis and pulmonary thromboembolism when treated in the inpatient setting. The choice of the cost reduction method is conditioned by the evidence from the randomized controlled studies EINSTEIN DVT and EINSTEIN PE, stating that rivaroxaban is no less effective compared with enoxaparin in combination with warfarin. The difference in the cost of the drugs is calculated from the healthcare perspective taking into account the risk of major bleeding. The price values were sourced from public procurement tenders (zakupki.gov.ru) in quarters I-IV 2013 and quarter I 2014. Costs associated with the treatment of major bleeding were defined on the basis of the obligatory medical insurance rates for Moscow in 2013. The authors demonstrated that use of rivaroxaban compared with enoxaparin and warfarin results in cost savings for the medicinal treatment of DVT and PTE in the amount of 2,020.71 and 3,353.35 rubles per patient, respectively. The revealed pattern is resistant to real-life fluctuations in prices for medicines. |
topic |
анализ минимизации затрат тромбоз глубоких вен (тгв) тромбоэмболия легочных артерий (тэла) ривароксабан эноксапарин варфарин cost reduction evaluation deep vein thrombosis (dvt) pulmonary thromboembolism (pte) rivaroxaban enoxaparin warfarin |
url |
https://www.med-sovet.pro/jour/article/view/610 |
work_keys_str_mv |
AT mvavksentyeva pharmacoeconomicevaluationoftreatingacutevenousthromboembolismwithrivaroxabanintheinpatientsetting AT ovshatalova pharmacoeconomicevaluationoftreatingacutevenousthromboembolismwithrivaroxabanintheinpatientsetting |
_version_ |
1721274630867517440 |